Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Aquestive Therapeutics Inc’s stock clocked out at $5.77, down -1.87% from its previous closing price of $5.88. In other words, the price has decreased by -$1.87 from its previous closing price. On the day, 2.34 million shares were traded. AQST stock price reached its highest trading level at $5.9254 during the session, while it also had its lowest trading level at $5.61.
Ratios:
To gain a deeper understanding of AQST’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.18 and its Current Ratio is at 3.53.
On December 17, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $17.
On May 10, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $8.Leerink Partners initiated its Outperform rating on May 10, 2024, with a $8 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 26 ’25 when Barber Daniel sold 91,343 shares for $6.03 per share. The transaction valued at 551,191 led to the insider holds 923,430 shares of the business.
Boyd Peter E. sold 10,000 shares of AQST for $63,000 on Sep 26 ’25. The insider now owns 278,323 shares after completing the transaction at $6.30 per share. On Sep 26 ’25, another insider, Peter Boyd, who serves as the Officer of the company, bought 10,000 shares for $6.30 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AQST now has a Market Capitalization of 698017856 and an Enterprise Value of 555127360. For the stock, the TTM Price-to-Sale (P/S) ratio is 15.82. Its current Enterprise Value per Revenue stands at 12.579 whereas that against EBITDA is -10.677.
Stock Price History:
The Beta on a monthly basis for AQST is 1.77, which has changed by 0.16565657 over the last 52 weeks, in comparison to a change of 0.16766965 over the same period for the S&P500. Over the past 52 weeks, AQST has reached a high of $6.43, while it has fallen to a 52-week low of $2.12. The 50-Day Moving Average of the stock is 28.21%, while the 200-Day Moving Average is calculated to be 67.00%.
Shares Statistics:
It appears that AQST traded 2.25M shares on average per day over the past three months and 5197010 shares per day over the past ten days. A total of 120.97M shares are outstanding, with a floating share count of 112.21M. Insiders hold about 7.25% of the company’s shares, while institutions hold 37.60% stake in the company. Shares short for AQST as of 1757894400 were 8880063 with a Short Ratio of 3.95, compared to 1755216000 on 8411354. Therefore, it implies a Short% of Shares Outstanding of 8880063 and a Short% of Float of 8.430000399999999.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 2.0 analysts currently analyzing and rating the stock of Aquestive Therapeutics Inc (AQST).The consensus estimate for the next quarter is -$0.12, with high estimates of -$0.12 and low estimates of -$0.13.
Analysts are recommending an EPS of between -$0.56 and -$0.6 for the fiscal current year, implying an average EPS of -$0.58. EPS for the following year is -$0.52, with 2.0 analysts recommending between -$0.4 and -$0.65.
Revenue Estimates
In. The current quarter, 10 analysts expect revenue to total $12.94M. It ranges from a high estimate of $15.17M to a low estimate of $10.79M. As of. The current estimate, Aquestive Therapeutics Inc’s year-ago sales were $13.54MFor the next quarter, 10 analysts are estimating revenue of $13.34M. There is a high estimate of $17.9M for the next quarter, whereas the lowest estimate is $10.82M.
A total of 10 analysts have provided revenue estimates for AQST’s current fiscal year. The highest revenue estimate was $50.9M, while the lowest revenue estimate was $40.33M, resulting in an average revenue estimate of $44.98M. In the same quarter a year ago, actual revenue was $57.56MBased on 10 analysts’ estimates, the company’s revenue will be $62.11M in the next fiscal year. The high estimate is $77M and the low estimate is $36.85M.
